The authorization follows results from the Phase 3 WIL-33 clinical trial, which evaluated the safety and efficacy of the therapy in 12 young patients diagnosed with severe von Willebrand Disease. During the 12-month study, participants received intravenous infusions two to three times per week. Data indicated a low annualized bleeding rate of 4.6, with nearly all reported bleeding episodes classified as minor.
FDA Approves wilate for Prophylactic Treatment in Young Children
The U.S. Food and Drug Administration has expanded the approval of Octapharma’s wilate, making it the first von Willebrand Factor concentrate cleared for routine prophylaxis in children younger than 6. This regulatory milestone provides a long-sought preventative option for the most common inherited bleeding disorder in early childhood.
Principal investigator Akshat Jain noted that the trial provides the necessary pharmacokinetic evidence to confirm that prophylaxis is both well-tolerated and effective in this age group. Before this expansion, pediatric hematologists lacked an FDA-approved routine preventative treatment for their youngest patients. The findings align with existing clinical outcomes observed in older children and adults, with no instances of thrombotic events or Factor VIII accumulation recorded during the study.
Comments (0)
No comments yet. Be the first!